Endoluten
Pineal peptide bioregulator
Endoluten is a pineal peptide complex — an extract. It matters on this site for one reason above all others: the human trial record everyone attaches to Epitalon was generated on a pineal extract, not on the tetrapeptide. If that record belongs to any product sold today, it belongs to this class rather than to the synthetic peptide.
Endoluten quick facts
| Reported research dose (Injectable) | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~20-40 min |
| Forms | Injectable, Oral |
| Evidence level | Russian studies; limited |
| Other forms available | Oral — dosed differently |
The pineal/longevity centerpiece of Khavinson protocols — run in courses. The centrepiece of most Khavinson protocols and effectively the peptide-bound version of the Epitalon idea — running both is duplication. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, sleep quality and, if you want a number, IGF-1 and a fasting insulin as general metabolic context. Run it as an experiment you measure, not a protocol you trust.
What Endoluten actually is — and why that changes the mechanism
Endoluten is a pineal peptide complex — an extract, not a molecule. There is no sequence to state, no mass to confirm, and no single structure to model. What there is instead is the most tangled attribution problem in this catalog, and untangling it is the most useful thing this page can do.
Three names, two products, one body of evidence. Epithalamin is the pineal extract used in the human trials. Epitalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly. Endoluten is a commercial pineal peptide complex. The 266-subject elderly series that every longevity claim in this field traces back to used Epithalamin. It did not use Epitalon and it did not use Endoluten. Vendors move that evidence between all three names as though they were interchangeable. They are not: an extract made to one process is not a synthetic peptide, and it is not automatically another manufacturer's extract either.
What the proposed mechanism actually is. The gene-regulation review attributes pineal activity to Ala-Glu-Asp-Gly acting on the circadian genes Clock, Csnk1e and Cry2 in leukocytes and blood lymphocytes, and restoring the melatonin-forming function of the pineal gland. Note what has happened there: a claim about the synthetic tetrapeptide is being used to explain the extract. That is only valid if the extract contains meaningful quantities of that tetrapeptide, which no published assay of any commercial pineal complex has ever demonstrated.
Why a peptide complex cannot inherit the sequence argument. The whole short-peptide mechanism — groove binding, chromatin interaction, computed DNA affinity — is an argument about defined molecules of two to four residues. An extract is a mixture of peptides across a range of lengths, and no member of that mixture has been identified in a commercial pineal product by mass spectrometry in the public literature. The mechanism belongs to a molecule this product has not been shown to contain.
What the primary literature on Endoluten actually says
Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
Epithalamin, the pineal extract, in 266 elderly subjects over 6–8 years. Reported mortality 1.6–1.8-fold lower than control on the extract alone, 2.5-fold lower combined with the thymus extract, 4.1-fold lower with annual combined courses over six years. Acute respiratory disease incidence 2.0–2.4-fold lower.
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
The mechanism the pineal claim rests on: AEDG acting on Clock, Csnk1e and Cry2 with restored melatonin production. Note that this is a claim about the synthetic tetrapeptide, being used to explain an extract.
The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Cited as a calibration point rather than as evidence about this product. When an independent group systematically reviewed animal-derived preparations in cognitive disorders, the verdict across the class was that 'risk of bias was moderate to high, there was imprecision, and certainty of evidence was considered low to very low.'
What is not here. Nothing is indexed under the trade name Endoluten. The pineal-extract human data is published on Epithalamin. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Endoluten evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Endoluten. Endoluten's evidence problem is inherited rather than its own. The 6–8 year series has no randomization described, no blinding, no pre-registration and post-hoc endpoints, and reports an all-cause mortality effect larger than any accepted intervention in medicine. It has not been replicated outside the originating group in more than twenty years. And it was run on Epithalamin — a product from the same tissue and the same institute, not necessarily the same preparation as what is sold under this name now.
What the data does support. Khavinson and Morozov followed 266 elderly subjects over 6–8 years on Epithalamin, Thymalin, or both. Reported outcomes: acute respiratory disease incidence 2.0–2.4-fold lower; mortality 1.6–1.8-fold lower with the pineal extract alone, 2.5-fold lower with both extracts, and 4.1-fold lower with annual combined courses over six years.
Why those numbers should make you more skeptical, not less. A 4.1-fold reduction in all-cause mortality is larger than any intervention in the history of medicine — larger than statins, larger than smoking cessation, larger than antihypertensives. When an uncontrolled, unblinded, non-pre-registered series from a single institute produces an effect that size, the most likely explanation is the design rather than the drug. That is not a claim that the compound does nothing; it is a claim that this study cannot tell you what it does.
The specific epistemic position: the human data belongs to Epithalamin, not to this trade name; the mechanism belongs to Epitalon, not to this trade name; and nothing is indexed under Endoluten itself. This is a product assembled out of other products' evidence. There is no negative trial to point at — but there is no trial of this at all.
What is actually measured, and what is not. Measured, for Epithalamin in an uncontrolled series: 266 subjects over 6–8 years, acute respiratory disease 2.0–2.4-fold lower, mortality 1.6–1.8-fold lower alone and 4.1-fold lower with annual combined courses. Not measured for this product: anything. Not measured for any pineal complex: composition by mass spectrometry, plasma half-life, clearance, oral bioavailability, or whether the preparation contains the tetrapeptide its mechanism section is written about.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Endoluten pharmacokinetics — how much of it actually gets in
Why there is no half-life, and why the blank is the wrong place to stop. A half-life describes one compound's clearance. A peptide mixture has as many clearance curves as it has components, so the “~20-40 min” in the quick facts above is a number for something unspecified. There is no traceable human pharmacokinetic study of any commercial pineal complex.
What can still be reasoned. Peptide components in an extract meet the same serum aminopeptidases as anything else and clear in minutes. That is not fatal to the claim — a transcriptional signal does not have to persist in blood for its effect to appear, which is exactly why the studied pattern is a short course rather than continuous use. It does mean serum measurement would tell you nothing, and it means the interesting number is not clearance but delivery.
The route arithmetic, and it does not add up. Endoluten is sold in both injectable and oral form. An injection is 100% bioavailable by definition — it bypasses gastric acid, pancreatic proteases, the brush-border peptidase layer and hepatic first-pass entirely. A swallowed capsule survives none of those for free. The named mechanism that lets a peptide cross the gut wall intact is PEPT1, which carries di- and tripeptides — not peptide mixtures of unknown chain length, and not proteins. So for the oral form to deliver comparable systemic exposure, some unmeasured fraction of the complex would have to survive digestion and arrive intact. Nobody has published that fraction for this product or any product like it. Naming the bound is honest; the two routes being quoted at comparable amounts is not.
The ratio the catalog itself implies. Across this class, the oral products carry a median of roughly 29x more material per day than the injectable ones. Nobody arrived at that by measuring absorption — no oral bioavailability figure has been published for any compound in this family — but the gap is the vendors' own implicit answer to the question: swallowing it is assumed to deliver a small fraction of what an injection delivers, and an injection is fully bioavailable by definition. Treat that as a bound on the plausible exposure, not as a measurement, because a measurement is exactly what is missing.
What would have to be true for Endoluten to work
What would have to be true. The commercial complex would have to contain short peptides at meaningful concentration — unverified; those peptides would have to reach target tissue after the route used — unmeasured; enter cells and nuclei — undescribed; and shift circadian gene transcription enough to change a hormone you can measure. The pineal claim is unusually lucky here, because its proposed output is melatonin, and melatonin timing is directly measurable.
These are the tests that would move the pineal claim from inherited evidence to evidence of its own.
- Prediction 1 — dim light melatonin onset. should shift earlier if the pineal claim is real, within one course. The single most direct test available, and cheaper than most of the supplements people stack around it.
- Prediction 2 — 6-sulfatoxymelatonin. overnight urinary output should rise, within one course. A urine collection, not a blood draw. If melatonin output does not change, the entire pineal framing is doing no work.
- Prediction 3 — IGF-1 (Insulin-like Growth Factor 1). should not move, over any course. A negative control for contamination. Bioregulator vials mislabelled as growth-axis peptides is the failure mode this catches.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Endoluten did to it — and that difference is the entire point of testing.
Endoluten versus the alternatives
Endoluten versus Epitalon — the comparison the whole category rests on. Epitalon is a defined tetrapeptide with a registered chemical identity and no human outcome trial. Endoluten is an extract with no verifiable identity whose class carries the 266-subject series. The argument for the extract is that it works through peptides like Epitalon; if that is true, the defined peptide should do the same job and be checkable, and the extract is the worse buy. If it is false, then most of the mechanistic writing in this field — including the sections above — is explaining an extract with a molecule that has nothing to do with it. Nobody has run them head to head in a human. That single trial would resolve more of this field than anything else anyone could fund.
And against the credible alternative. If the goal is sleep or circadian timing, melatonin itself and timed light exposure have direct human trial data, cost almost nothing, and have measurable effects on the same endpoints this compound is claimed to move. On evidence they win outright.
What you are actually buying when you buy Endoluten
Endoluten is an extract, not a molecule, and that single fact governs what any certificate of analysis is worth. A CoA on a tissue extract can establish sterility, endotoxin, total protein and the absence of named contaminants. It cannot establish identity, because there is no formula to check against — the product is defined by its process. Two vials with clean certificates can hold different mixtures, and no laboratory test resolves that.
Which is why the naming problem is not pedantry. The trial evidence attaches to Epithalamin, made to one process at one institute. With no assay that can compare one pineal complex to another, there is no way — even in principle — to establish that a commercial product is the same thing the trial used. For a synthetic peptide that question has an answer: run the mass spectrum. Here it does not.
Same limit as every extract: a certificate of analysis can show sterility, endotoxin and total protein, and cannot show identity, because there is no single molecule to identify. Ask what tissue, what species, and what the extraction process was — those three answers define the product more than any number on the CoA does.
Where to get Endoluten
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Endoluten
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- The flagship of the series, and the one with the most ambitious claim attached. It is the pineal extract from which Epitalon — the defined tetrapeptide with the telomerase literature — was derived, so the two are constantly conflated in marketing.
- They are not the same thing. Epitalon is a known sequence with published in-vitro telomerase data; Endoluten is the extract it came from. If you want the mechanism people are buying, Epitalon is the defined version of it.
🧪 Theoretical / extrapolated
- A pineal peptide preparation proposed to restore melatonin rhythm and act on telomere maintenance. Pineal function does decline with age and melatonin rhythm flattening is well documented, so the target is legitimate.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
- Telomerase activation is not automatically a good thing — it is also how many cancer cells achieve immortality. Any compound sold on that mechanism carries that question, and nobody has answered it in humans.
What that tier rests on here. The tier above borrows from Epithalamin for its human data and from Epitalon for its mechanism. Neither is this product. Nothing is indexed under the trade name Endoluten.
How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
Start with the human study, because Endoluten's tissue has the best one in the entire class. Korkushko 2011 reports a randomized comparative study in elderly coronary patients: 39 received courses of the pineal extract on top of basic therapy over three years, 40 received basic therapy alone, and the cohort was followed for fifteen years. The authors report slower cardiovascular aging, preserved physical endurance, a normalized melatonin circadian rhythm, changes in carbohydrate and lipid metabolism — and significantly lower mortality in the treated arm.
Now read the same sentence again. Seventy-nine people. One center. No blinding described. No pre-registered protocol, and a mortality endpoint reported alongside a dozen others. A mortality signal from 79 patients is a reason to run a bigger trial, not a result to act on — and in the fifteen years since, no group outside this one has attempted it.
The biomarker chain underneath it is the real asset. Goncharova 2003 took the pineal preparation into monkeys; Korkushko 2007 reported, in both old monkeys and elderly people, that night melatonin and circadian amplitude fall with age and that the pineal peptides restore night release; Trofimova 2017 reported increased pineal melatonin synthesis in elderly people under a related preparation. Rat work goes back to Slepushkin 1983. That is a species ladder with a measurable hormone at every rung — and no other product on this site has one.
Where it stops. Every link is the same institute, and none of it was run on Endoluten. It was run on Epithalamin and its relatives Khavinson 2002. The capsule and the injectable extract share a tissue of origin and a manufacturer, not a dataset.
What nobody has tested yet
Overnight urinary 6-sulfatoxymelatonin, before and after. It is the standard non-invasive index of melatonin output, it needs no blood draw and no overnight clinic stay, and it measures precisely what fifty years of this group's argument predicts should move. Not one published study of the capsule has run it.
The comparison nobody has made, and it is unflattering. Melatonin itself is available over the counter, costs almost nothing, and raises circulating melatonin far more reliably than any peptide could. If the pineal claim is that night melatonin is what matters, then the honest head-to-head is peptide against the hormone, and it has never been run. If the claim is instead that restoring the gland's own rhythm differs from supplying the hormone — which is the interesting version — then dim-light melatonin onset is the measurement that separates them, and nobody has published that either.
Extrapolation, labeled as such. If the mechanism is genuinely restorative rather than substitutive, the effect should persist after a course ends and should be larger in people whose baseline night melatonin is lowest. Both predictions are testable with the same urine test twice, and both would be false if the numbers snap back within days of stopping. No published series has reported a washout at all.
Sources read for this page
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bulletin of Experimental Biology and Medicine 2011 · PMID 22451889
- Korkushko OV. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Advances in Gerontology 2007 [Russian] · PMID 17969590
- Trofimova SV. Pineamin increased pineal melatonin synthesis in elderly people. Advances in Gerontology 2017 [Russian] · PMID 28849889
- Goncharova ND. Peptide correction of age-related pineal disturbances in monkeys. Advances in Gerontology 2003 [Russian] · PMID 14743609
- Khavinson VKh, Morozov VG. Geroprotective effect of thymalin and epithalamin. Advances in Gerontology 2002 [Russian] · PMID 12577695
- Slepushkin VD. Effect of epithalamin on the course of traumatic shock in rats. Patologicheskaia Fiziologiia i Eksperimentalnaia Terapiia 1983 [Russian] · PMID 6646823
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
Endoluten — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Endoluten — safety specifics for this compound
Specific to Endoluten: it is a bovine-derived tissue extract taken from an endocrine organ, which is a different risk category from the synthetic peptides nearby — animal-source biologics carry protein- allergy and immunogenicity risk that a synthesized tetrapeptide does not. The specific unknown is mechanistic rather than toxicological: an agent proposed to shift circadian gene expression and melatonin timing could plausibly move sleep phase in the wrong direction, and nothing in the literature has measured that in anyone. The 266-subject Khavinson and Morozov follow-up over 6–8 years is the closest thing to a safety record this class has, and it is not one: it reports mortality 1.6–1.8-fold lower on the pineal extract, but no adverse-event table, no dropout accounting and no independent adjudication, so a favorable mortality number is being read as a tolerability finding it was never designed to be. An endocrine-organ extract also has an obvious unmeasured axis — melatonin and the HPA axis — and 0 published studies have measured either before and after.
Endoluten — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Endoluten moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Endoluten in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Endoluten
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Endoluten — frequently asked questions
Is Endoluten a peptide or an extract?
An extract — a peptide complex from pineal gland, not a single defined molecule. That is why a certificate of analysis cannot confirm its identity the way it can for a synthetic peptide.
Is there a human trial of Endoluten?
Nothing is indexed under the trade name Endoluten. The pineal-extract human data is published on Epithalamin.
What should I measure if I run Endoluten?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Khavinson VKh, Morozov VG — Peptides of pineal gland and thymus prolong human life · Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Endoluten inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Endoluten is used for
Endoluten appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Endoluten is the endocrine & reproductive arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.